Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 7/20 | 0.41 |
| ▸ | ELANE | P08246 | 4/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 4/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5180557 | 0.95 | ELANE (0.38) | ROCK2ELANEGSK3BDYRK1AP2RX3 | |
| SCHEMBL5163793 | 0.86 | ROCK2 (0.42) | ROCK2ELANEP2RX3 | |
| SCHEMBL5178983 | 0.85 | ELANE (0.37) | ROCK2ELANE | |
| SCHEMBL5178175 | 0.85 | ELANE (0.36) | ROCK2ELANE | |
| SCHEMBL5167694 | 0.83 | ROCK2 (0.41) | ROCK2ELANE | |
| SCHEMBL5167282 | 0.82 | JAK3 (0.44) | ROCK2ELANEGSK3BDYRK1A | |
| SCHEMBL5606187 | 0.82 | POLB (0.44) | ROCK2GSK3BDYRK1AP2RX3POLB | |
| SCHEMBL5846130 | 0.82 | POLB (0.39) | ROCK2ELANEGSK3BDYRK1AP2RX3 | |
| SCHEMBL5606422 | 0.82 | POLB (0.44) | ROCK2GSK3BDYRK1AP2RX3POLB | |
| SCHEMBL1737749 | 0.82 | POLB (0.44) | ROCK2GSK3BDYRK1AP2RX3POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1768975-A2 | PYRIDYL PIPERAZINES FOR THE TREATMENT OF CNS DISORDERS | Pfizer Products Inc. (US) | 2007-04-04 | — | — | EP | claimed |
| US-20060025421-A1 | Pyridyl piperazines for the treatment of CNS disorders | PFIZER INC | 2006-02-02 | — | — | US | claimed |
| WO-2006000912-A2 | PYRIDYL PIPERAZINES FOR THE TREATMENT OF CNS DISORDERS | PFIZER PRODUCTS INC. (US) | 2006-01-05 | — | — | WO | claimed |
| EP-1768975-A2 | PYRIDYL PIPERAZINES FOR THE TREATMENT OF CNS DISORDERS | Pfizer Products Inc. (US) | 2007-04-04 | — | — | EP | disclosed |
| US-20060025421-A1 | Pyridyl piperazines for the treatment of CNS disorders | PFIZER INC | 2006-02-02 | — | — | US | disclosed |
| WO-2006000912-A2 | PYRIDYL PIPERAZINES FOR THE TREATMENT OF CNS DISORDERS | PFIZER PRODUCTS INC. (US) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025421-A1 | Pyridyl piperazines for the treatment of CNS disorders | TPH2, HTR1A, TPH1 | ROCK2 769/4885ELANE 4841/4885GSK3B 614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.